Patents

US 11221329 B2: Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity

Granted
2022-01-11
Filed
2016-10-27 application 15771857
Type
Utility · 20 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.

Source: PVGPATDIS, file of 2026-04-10 (ipg220111.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Lieber Institute, Inc. 9 patentsUS company or organizationBaltimore, MDLIEBER INSTITUTE INC Nonprofit EXACT high confidence: identical full name and statePVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Brady MaherBaltimore, MD1PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
G01NInvestigating or analysing materials by determining their chemical or physical propertiesG01N33/5058PVGPATDIS, file of 2026-04-10
A61KPreparations for medical, dental or toiletry purposesA61K9/0019PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P25/18PVGPATDIS, file of 2026-04-10
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms ; compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processesC12Q1/6883PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2020-12-28Name change
Change of name
LIEBER INSTITUTE FOR BRAIN DEVELOPMENT signed 2011-08-30LIEBER INSTITUTE, INC. BALTIMORE, MD54857/413ECORSEXC, file of 2026-09-25
2018-05-08Assignment
Assignment of assignor's interest
MAHER, BRADY signed 2018-05-07LIEBER INSTITUTE FOR BRAIN DEVELOPMENT BALTIMORE, MD45744/174ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.